San Francisco, CA— Biotechnology company Noetik has named Dr. Emily Corse as its new Executive Vice President of Therapeutics, a move aimed at accelerating the company’s AI-powered cancer drug development efforts.
In her new role, Dr. Corse will oversee Noetik’s therapeutics pipeline, guiding programs from early discovery through translational development and into initial clinical trials.
Dr. Corse, who trained under Nobel Laureate Dr. Jim Allison, previously led a research group at MD Anderson Cancer Center focused on immune biology and cancer therapies. She later held senior leadership positions at Roche and Boehringer-Ingelheim, where she managed cancer immunology programs spanning from drug discovery to early-phase clinical testing. Most recently, she served as Executive Vice President of Biology and Translation at Larkspur Biosciences.
“Emily is an exceptional leader with deep expertise in cancer immunotherapy,” said Dr. Ron Alfa, CEO and Co-Founder of Noetik. “Her clarity of vision and operational experience will be key as we move our AI-driven insights into innovative cancer treatments.”
Noetik, which describes itself as an “AI-native” biotech firm, is focused on using machine learning and proprietary datasets to develop precision cancer therapies. The company says Corse’s appointment underscores its goal of building a best-in-class therapeutic engine grounded in data-driven discovery.
“I’m thrilled to join Noetik at this pivotal stage,” said Dr. Corse in a statement. “The scientific foundation and platform capabilities here are the future of drug development. I look forward to advancing a pipeline that leverages deep biology and innovative data science to make a difference for patients.”
